Saying 'No' to PrEP Research in Malawi: What Constitutes 'Failure' in Offshored HIV Prevention Research?

Between 2004 and 2005, the first multi-sited clinical trial tested whether an existing, marketed antiretroviral drug, Tenofovir (TDF), could prevent HIV transmission. Referred to as pre-exposure prophylaxis (PrEP), most of these trial sites prematurely closed down. Two sites located in Cambodia and Cameroon received international media attention. But little attention was drawn to sites in Malawi and Nigeria, where university ethicists and research scientists extensively debated PrEP. 

This article focuses on events that took place in Malawi where there was a prolonged dispute over the scientific rationales of PrEP and not trial specific ethics referred to as 'bioethics'. Specifically, the article discusses debates pertaining to three PrEP trial protocols that were refused ethics approval in Malawi between 2004 and 2009. 

It is argued that HIV science debates in Malawi are embedded in postcolonial politics - geopolitical histories and state and household economic dispossessions that have created the structural possibilities for Malawi to become an offshore destination for HIV clinical research. As such, ethics in this case does not pertain to trial or bioethical 'failures'. Rather, ethics is located at the scale of imperial relations that give rise to multiple, often invisible, research concerns and constraints.

Via: http://goo.gl/aMLW1m  Purchase full article at: http://goo.gl/XLgdYt

By: Peterson K1, Folayan MO2, Chigwedere E3, Nthete E4.

• 1a Anthropology Department , University of California , 3151 Social Sciences Plaza, Irvine , CA , USA.
• 2b Institute of Public Health , Obafemi Awolowo University , Ile-Ife , Nigeria.
• 3c V&E Consultants , PO Box 31400, Lilongwe 3 , Malawi.
• 4d Malawi College of Health Sciences (Lilongwe Campus) , P.O. Box 30368, Lilongwe 3 , Malawi. 

More at:  https://twitter.com/hiv_insight